United Therapeutics Corporation (UTHR) — Cash Flow-to-Debt Ratio
United Therapeutics Corporation (UTHR) has a Cash Flow-to-Debt Ratio of 0.74x as of September 2025, meaning its operating cash flow of $562.10 Million could theoretically repay 1% of its total liabilities ($760.90 Million) in one year. See UTHR cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
United Therapeutics Corporation Cash Flow-to-Debt Ratio (1998–2024)
Historical debt coverage capacity for United Therapeutics Corporation across 27 annual periods. Also explore United Therapeutics Corporation (UTHR) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for United Therapeutics Corporation (1998–2024)
Year-by-year debt coverage analysis for United Therapeutics Corporation. For market capitalisation and broader financial context, see UTHR company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.44x | $1.33 Billion | $920.00 Million | ▲ +74.4% |
| 2023 | 0.83x | $978.00 Million | $1.18 Billion | ▲ +28.6% |
| 2022 | 0.64x | $802.50 Million | $1.25 Billion | ▲ +30.1% |
| 2021 | 0.49x | $598.20 Million | $1.21 Billion | ▼ -20.2% |
| 2020 | 0.62x | $755.70 Million | $1.22 Billion | ▲ +439.8% |
| 2019 | -0.18x | $-206.60 Million | $1.13 Billion | ▼ -114.3% |
| 2018 | 1.27x | $778.40 Million | $612.40 Million | ▲ +108.4% |
| 2017 | 0.61x | $474.20 Million | $777.60 Million | ▼ -56.1% |
| 2016 | 1.39x | $643.60 Million | $463.40 Million | ▲ +112.2% |
| 2015 | 0.65x | $382.80 Million | $584.80 Million | ▲ +14.0% |
| 2014 | 0.57x | $355.30 Million | $618.84 Million | ▲ +5.7% |
| 2013 | 0.54x | $425.27 Million | $783.26 Million | ▼ -10.8% |
| 2012 | 0.61x | $323.63 Million | $531.73 Million | ▲ +38.6% |
| 2011 | 0.44x | $250.19 Million | $569.59 Million | ▲ +13.7% |
| 2010 | 0.39x | $211.53 Million | $547.75 Million | ▲ +54.3% |
| 2009 | 0.25x | $99.72 Million | $398.54 Million | ▲ +285.0% |
| 2008 | -0.14x | $-49.20 Million | $363.62 Million | ▼ -180.5% |
| 2007 | 0.17x | $48.95 Million | $291.23 Million | ▼ -6.8% |
| 2006 | 0.18x | $49.39 Million | $273.94 Million | ▼ -93.2% |
| 2005 | 2.65x | $43.17 Million | $16.31 Million | ▲ +97.7% |
| 2004 | 1.34x | $20.78 Million | $15.52 Million | ▲ +283.5% |
| 2003 | -0.73x | $-8.56 Million | $11.74 Million | ▲ +57.7% |
| 2002 | -1.72x | $-22.26 Million | $12.91 Million | ▲ +30.3% |
| 2001 | -2.47x | $-38.90 Million | $15.72 Million | ▼ -26.5% |
| 2000 | -1.96x | $-31.11 Million | $15.91 Million | ▲ +48.0% |
| 1999 | -3.76x | $-23.70 Million | $6.30 Million | ▲ +21.6% |
| 1998 | -4.80x | $-9.60 Million | $2.00 Million | — |